UFA, 4 February 2015. /Bashinform News Agency, Elmira Sabirova/. A decision to give the regions the right to choose the state pharmaceuticals operator on supplying pharmaceutical drugs to preferential categories of citizens and medical institutions can be an effective step in prices monitoring. This proposal the Head of Bashkortostan Rustem Khamitov announced at a meeting on the development of anti-crisis measures in the health sector under the chairmanship of the of the Russian Prime Minister Dmitry Medvedev, held in Ufa on Tuesday, February 3.
According to the President of the Republic, last year the drugs price in the region grew by less than 0.5 percent, in January the weighted average price rose by two percent, but for some drugs – by 11 percent and higher.
“Purchasing of drugs for federal and regional benefit recipients was held in the first half of the last year, in fact, at the old prices. Nevertheless, we switched to a centralized procurement through the relevant department of the Ministry of Health RB. This gave us 10 percent savings. We buy medicines for 7 billion rubles, 700 million rubles are savings”, Rustem Khamitov said.
Another topic mentioned by the Head of the Republic was public-private partnerships in construction of health care facilities.
Speaking about the problems, the Rustem Khamitov noted that under the circumstances the cost-based part of the state guarantees program should be indexed not once a year, as it was before, but on a quarterly basis.
Rustem Khamitov also drew attention to the provision of high-tech medical care. Last year nearly 7,000 citizens of the republic received such care. Thus, 60 million rubles were allocated from the federal budget, 240 million rubles - from the Fund of Obligatory Medical Insurance and 500 million rubles - from the republican treasury. This year there is no such support.
As the head of the region marked, the number of high-tech surgeries will reduce by two or three times. In addition, it can cause an outflow of highly qualified specialists.
In addition, Rustem Khamitov considered it necessary to simplify the procurement procedure of medicines rising in price as part of the federal law on the procurement system.
Another issue was supporting domestic producers of medicines, for example, such as Ufa pharmaceutical company "Ufa-Vita", "Microgen" branch - "Immunopreparat", which can produce drugs cheaper than imported counterparts, but currently they need state support.
“We need a target-oriented, direct support for this kind of business,” Rustem Khamitov said.
